VRTX icon

Vertex Pharmaceuticals
VRTX

Upgrade to unlock
Buy
Hold
Sell

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$536
8% upside
High target

13 analyst ratings

positive
3  neutral
23%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Canaccord Genuity
Canaccord Genuity
Whitney Ijem
17 Feb ‘26 11 days ago
Barclays
Barclays
Eliana Merle
100% 1-yr VRTX win rate
17 Feb ‘26 11 days ago
HC Wainwright & Co
HC Wainwright & Co
Andrew Fein
75% 1-yr VRTX win rate
17 Feb ‘26 12 days ago
Scotiabank
Scotiabank
Greg Harrison
13 Feb ‘26 15 days ago
RBC Capital
RBC Capital
Brian Abrahams
100% 1-yr VRTX win rate
13 Feb ‘26 15 days ago
Stifel
Stifel
Paul Matteis
13 Feb ‘26 15 days ago
Oppenheimer
Oppenheimer
Jay Olson
100% 1-yr VRTX win rate
13 Feb ‘26 15 days ago
UBS
UBS
Michael Yee
100% 1-yr VRTX win rate
26 Jan ‘26 1 month ago
Evercore ISI Group
Evercore ISI Group
Liisa Bayko
100% 1-yr VRTX win rate
23 Jan ‘26 1 month ago
Bernstein
Bernstein
William Pickering
100% 1-yr VRTX win rate
12 Jan ‘26 1 month ago
Wolfe Research
Wolfe Research
Andy Chen
100% 1-yr VRTX win rate
6 Jan ‘26 1 month ago
Leerink Partners
Leerink Partners
David Risinger
100% 1-yr VRTX win rate
29 Dec ‘25 2 months ago
Wells Fargo
Wells Fargo
Mohit Bansal
100% 1-yr VRTX win rate
10 Dec ‘25 2 months ago
Morgan Stanley
Morgan Stanley
Terence Flynn
100% 1-yr VRTX win rate
5 Dec ‘25 2 months ago